MA48461A - Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation - Google Patents

Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation

Info

Publication number
MA48461A
MA48461A MA048461A MA48461A MA48461A MA 48461 A MA48461 A MA 48461A MA 048461 A MA048461 A MA 048461A MA 48461 A MA48461 A MA 48461A MA 48461 A MA48461 A MA 48461A
Authority
MA
Morocco
Prior art keywords
excipients
viscosity
reduce
antibody formulations
formulation compositions
Prior art date
Application number
MA048461A
Other languages
English (en)
Inventor
Robert Matthew Fesinmeyer
Jian Hua Gu
Rulin Qian
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA48461A publication Critical patent/MA48461A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA048461A 2017-04-28 2018-04-24 Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation MA48461A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762492049P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
MA48461A true MA48461A (fr) 2020-03-04

Family

ID=62148500

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048461A MA48461A (fr) 2017-04-28 2018-04-24 Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation

Country Status (4)

Country Link
US (2) US12257343B2 (fr)
EP (1) EP3615065A1 (fr)
MA (1) MA48461A (fr)
WO (1) WO2018200533A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109439536A (zh) * 2017-08-18 2019-03-08 黄国仁 饮用水细菌快速培养装置及菌落总数快速检测系统
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
TWI856084B (zh) * 2019-04-01 2024-09-21 美商建南德克公司 用於穩定含有蛋白質之配方之組合物及方法
EP4013786A1 (fr) * 2019-08-12 2022-06-22 Amgen Inc. Formulations d'anticorps anti-sclérostine
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
MX2022010012A (es) * 2020-02-13 2022-09-07 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria.
IL295511A (en) * 2020-02-18 2022-10-01 Amgen Inc Formulations of human anti-tslp antibodies and methods of using them
JP2023533704A (ja) * 2020-07-13 2023-08-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 高濃度タンパク質製剤用の粘度低減賦形剤及びそれらの組み合わせ
WO2023140807A1 (fr) * 2022-01-19 2023-07-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques de trastuzumab
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
US20260015427A1 (en) 2024-06-25 2026-01-15 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO2004039337A2 (fr) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Formulations pharmaceutiques liquides stables d'anticorps ayant tendance a l'isomerisation
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
CA2638811A1 (fr) 2006-02-03 2007-08-16 Medimmune, Llc Formulations de proteines
CA2790018C (fr) 2006-12-21 2015-02-03 Amgen Inc. Formulations
CA2674608A1 (fr) 2007-01-09 2008-07-17 Wyeth Preparations d'anticorps ant-il-13 et leurs utilisations
CA2682292A1 (fr) 2007-03-30 2008-10-09 Medimmune, Llc Formulation aqueuse comportant un anticorps anti-interferon alpha humain
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
EP2699265B1 (fr) * 2011-04-20 2019-10-16 Sandoz AG Formulations liquides pharmaceutiques stables de la protéine de fusion tnfr:fc
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015196091A1 (fr) 2014-06-20 2015-12-23 Reform Biologics, Llc Composés excipient réduisant la viscosité pour formulations à base de protéines
AU2015289874A1 (en) 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
WO2016065181A1 (fr) 2014-10-23 2016-04-28 Amgen Inc. Réduction de la viscosité de formulations pharmaceutiques
SI4190355T1 (sl) 2017-04-28 2025-02-28 Amgen Inc. Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe

Also Published As

Publication number Publication date
EP3615065A1 (fr) 2020-03-04
US20250367115A1 (en) 2025-12-04
US12257343B2 (en) 2025-03-25
US20200352857A1 (en) 2020-11-12
WO2018200533A1 (fr) 2018-11-01

Similar Documents

Publication Publication Date Title
MA48461A (fr) Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
MA49043A (fr) Formulation stable d'anticorps
EP3880688A4 (fr) Préparations et compositions d'oligosaccharides
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3840730A4 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
MA54052A (fr) Formulation d'anticorps
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
EP3518971A4 (fr) Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
MA55033A (fr) Formulation d'anticorps thérapeutique
EP3381451A4 (fr) Composition pharmaceutique utilisée pour réduire la graisse localisée et utilisation de la composition pharmaceutique
EP3684369A4 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
MA54139A (fr) Formulation d'anticorps
IL281938A (en) Stable semaglutide compositions and uses thereof
MA53466A (fr) Formulation stable d'anticorps anti-osmr
EP3688033A4 (fr) Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
EP3817750A4 (fr) Compositions d'associations de cannabidiol
EP3897593A4 (fr) Formulations de cannabinoïdes et compositions pharmaceutiques
EP3500291A4 (fr) Formulations pour l'administration par voie orale d'agents actifs